DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Janjigian YY, Maron SB, Chatila WK. et al.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Lancet Oncol 2020;
21 (06) 821-831
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.